PT2314321E - Elemento de encaminhamento de um fluido de refrigeração de uma ferramenta de corte e processo para este encaminhamento - Google Patents
Elemento de encaminhamento de um fluido de refrigeração de uma ferramenta de corte e processo para este encaminhamento Download PDFInfo
- Publication number
- PT2314321E PT2314321E PT100131804T PT10013180T PT2314321E PT 2314321 E PT2314321 E PT 2314321E PT 100131804 T PT100131804 T PT 100131804T PT 10013180 T PT10013180 T PT 10013180T PT 2314321 E PT2314321 E PT 2314321E
- Authority
- PT
- Portugal
- Prior art keywords
- connexins
- formulations
- reduction
- antisense nucleotides
- connexin
- Prior art date
Links
- 102000010970 Connexin Human genes 0.000 title abstract 3
- 108050001175 Connexin Proteins 0.000 title abstract 3
- 230000000692 anti-sense effect Effects 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000002773 nucleotide Substances 0.000 title 1
- 125000003729 nucleotide group Chemical group 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 230000003828 downregulation Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000003716 rejuvenation Effects 0.000 abstract 1
- 230000036573 scar formation Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000008719 thickening Effects 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ33392899 | 1999-01-27 | ||
NZ50019099 | 1999-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2314321E true PT2314321E (pt) | 2014-09-26 |
Family
ID=26652011
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT100131804T PT2314321E (pt) | 1999-01-27 | 2000-01-27 | Elemento de encaminhamento de um fluido de refrigeração de uma ferramenta de corte e processo para este encaminhamento |
PT05016736T PT1621212E (pt) | 1999-01-27 | 2000-01-27 | Formulações que contém nucleótidos anti-paralelos em relação a conexinas |
PT00901236T PT1146908E (pt) | 1999-01-27 | 2000-01-27 | Formulacoes que contem nucleotidos de anti-sentido para conexinas |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT05016736T PT1621212E (pt) | 1999-01-27 | 2000-01-27 | Formulações que contém nucleótidos anti-paralelos em relação a conexinas |
PT00901236T PT1146908E (pt) | 1999-01-27 | 2000-01-27 | Formulacoes que contem nucleotidos de anti-sentido para conexinas |
Country Status (13)
Country | Link |
---|---|
US (11) | US7098190B1 (pt) |
EP (3) | EP2314321B1 (pt) |
JP (4) | JP4994533B2 (pt) |
AT (2) | ATE300959T1 (pt) |
AU (1) | AU776512B2 (pt) |
CA (2) | CA2361251C (pt) |
CY (2) | CY1112557T1 (pt) |
DE (1) | DE60021700T2 (pt) |
DK (3) | DK1146908T3 (pt) |
ES (3) | ES2377749T3 (pt) |
NZ (1) | NZ513154A (pt) |
PT (3) | PT2314321E (pt) |
WO (1) | WO2000044409A1 (pt) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5991308A (ja) * | 1982-11-16 | 1984-05-26 | Kawasaki Heavy Ind Ltd | 平面の検出方法 |
WO2000044409A1 (en) * | 1999-01-27 | 2000-08-03 | University College London | Formulations comprising antisense nucleotides to connexins |
EP1197553A1 (en) * | 2000-10-12 | 2002-04-17 | A3D GmbH, Antisense Design & Drug Development | Antisense nucleic acid against alphaV integrin |
US20050119211A1 (en) * | 2001-05-18 | 2005-06-02 | Sirna Therapeutics, Inc. | RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA) |
EA015670B9 (ru) * | 2003-12-03 | 2012-01-30 | Коуда Терапьютикс (Нз) Лтд. | Антисмысловые соединения, нацеленные на коннексины, и способы их применения |
EP1827480B1 (en) | 2004-12-21 | 2016-11-09 | MUSC Foundation For Research Development | Compositions and methods for promoting wound healing and tissue regeneration |
US9408381B2 (en) | 2004-12-21 | 2016-08-09 | Musc Foundation For Research Development | Alpha Connexin c-Terminal (ACT) peptides for use in transplant |
WO2008157840A2 (en) * | 2007-06-21 | 2008-12-24 | Musc Foundation For Research Development | Alpha connexin c-terminal (act) peptides for treating age-related macular degeneration |
US9248141B2 (en) | 2005-02-03 | 2016-02-02 | Coda Therapeutics, Inc. | Methods of treatment by administering anti-connexin proteins and mimetics |
US20090163432A1 (en) * | 2005-11-08 | 2009-06-25 | Kansai Technology Licensing Organization Co., Ltd. | Therapeutic Agent for Corneal Diseases |
WO2007087113A2 (en) | 2005-12-28 | 2007-08-02 | The Scripps Research Institute | Natural antisense and non-coding rna transcripts as drug targets |
JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のsiRNAおよびその使用方法 |
KR20100027091A (ko) * | 2006-11-15 | 2010-03-10 | 코다 테라퓨틱스, 인크. | 상처 치유를 위한 개선 방법 및 조성물 |
AU2014204482B2 (en) * | 2006-12-11 | 2016-07-07 | Coda Therapeutics, Inc. | Anticonnexin polynucleotides as impaired wound healing compositions |
DK2101791T3 (en) | 2006-12-11 | 2015-01-05 | Coda Therapeutics Inc | ANTICONNEXIN POLYNUCLEOTIDES AS COMPOSITIONS AGAINST DEGRADED HEALTH |
JP5646997B2 (ja) | 2007-10-03 | 2014-12-24 | クォーク ファーマシューティカルズ インコーポレーティッドQuark Pharmaceuticals,Inc. | 新規siRNA構造 |
WO2009075881A2 (en) | 2007-12-11 | 2009-06-18 | Coda Therapeutics, Inc. | Impaired wound healing compositions and treatments |
US20100279921A1 (en) * | 2007-12-11 | 2010-11-04 | Coda Therapeutics, Inc. | Impaired wound healing compositions and treatments |
AU2008343754A1 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin polynucleotides for the treatment of surgical adhesions |
JP2011507861A (ja) * | 2007-12-21 | 2011-03-10 | コーダ セラピューティクス, インコーポレイテッド | 線維症性の状態の治療のための抗コネキシンポリヌクレオチド剤と組み合わせた抗コネキシンポリペプチド剤の使用 |
CA2710380A1 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin 43 poly nucleotide for the treatment of fibrotic conditions |
US20110245184A1 (en) * | 2007-12-21 | 2011-10-06 | Bradford James Duft | Treatment of surgical adhesions |
WO2009085277A2 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Treatment of abnormal or excessive scars |
WO2009085269A2 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin polynucleotides, peptides or antibodies for the treatment of orthopedic conditions |
CA2710386A1 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Improved medical devices |
EP2252320A2 (en) * | 2007-12-21 | 2010-11-24 | Coda Therapeutics, Inc. | Use of anti-connexin polynucleotides and peptides for the treatment of abnormal or excessive scars |
US20110243964A1 (en) * | 2007-12-21 | 2011-10-06 | Bradford James Duft | Treatment of orthopedic conditions |
US20110038920A1 (en) * | 2008-01-07 | 2011-02-17 | Ryoichi Mori | Wound healing compositions and treatments |
US10138485B2 (en) | 2008-09-22 | 2018-11-27 | Rxi Pharmaceuticals Corporation | Neutral nanotransporters |
ES2727549T3 (es) | 2008-10-03 | 2019-10-17 | Curna Inc | Tratamiento de las enfermedades relacionadas con la apolipoproteína a1 por inhibición del transcrito antisentido natural a la apolipoproteína a1 |
ES2600781T3 (es) | 2008-12-04 | 2017-02-10 | Curna, Inc. | Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf |
KR101829469B1 (ko) | 2008-12-04 | 2018-03-30 | 큐알엔에이, 인크. | Epo에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(epo) 관련된 질환의 치료 |
JP5923306B2 (ja) | 2008-12-04 | 2016-05-24 | クルナ・インコーポレーテッド | 腫瘍抑制遺伝子に対する天然アンチセンス転写物の抑制による腫瘍抑制遺伝子関連疾患の治療 |
US8669941B2 (en) * | 2009-01-05 | 2014-03-11 | Nuance Communications, Inc. | Method and apparatus for text entry |
WO2010093904A2 (en) | 2009-02-12 | 2010-08-19 | Curna, Inc. | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
EP2408919B1 (en) | 2009-03-16 | 2017-10-18 | CuRNA, Inc. | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
ES2627763T3 (es) | 2009-03-17 | 2017-07-31 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el homólogo tipo delta 1 (dlk1) por inhibición de transcrito antisentido natural a dlk1 |
CN102459596B (zh) | 2009-05-06 | 2016-09-07 | 库尔纳公司 | 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病 |
JP6250930B2 (ja) | 2009-05-06 | 2017-12-20 | クルナ・インコーポレーテッド | トリステトラプロリン(ttp)に対する天然アンチセンス転写物の抑制によるttp関連疾患の治療 |
EP2427554B1 (en) | 2009-05-08 | 2016-11-16 | CuRNA, Inc. | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family |
CN102575251B (zh) | 2009-05-18 | 2018-12-04 | 库尔纳公司 | 通过抑制针对重编程因子的天然反义转录物来治疗重编程因子相关的疾病 |
JP2012527248A (ja) | 2009-05-22 | 2012-11-08 | クルナ・インコーポレーテッド | 転写因子e3(tfe3)に対する天然アンチセンス転写物の阻害によるtfe3およびインスリン受容体基質2(irs2)関連疾患の処置 |
KR101704988B1 (ko) | 2009-05-28 | 2017-02-08 | 큐알엔에이, 인크. | 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료 |
WO2010148050A2 (en) | 2009-06-16 | 2010-12-23 | Curna, Inc. | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
CA2765509C (en) | 2009-06-16 | 2021-08-17 | Joseph Collard | Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1 |
KR101807323B1 (ko) | 2009-06-24 | 2017-12-08 | 큐알엔에이, 인크. | Tnfr2에 대한 천연 안티센스 전사체의 억제에 의한 종양 괴사 인자 수용체 2(tnfr2) 관련된 질환의 치료 |
CA2765815A1 (en) | 2009-06-26 | 2010-12-29 | Opko Curna, Llc | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
CA2768947C (en) | 2009-07-24 | 2018-06-19 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
EP2462229B1 (en) | 2009-08-05 | 2016-05-11 | CuRNA, Inc. | Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins) |
CN102625841A (zh) | 2009-08-11 | 2012-08-01 | 欧科库尔纳有限责任公司 | 通过抑制脂连蛋白(adipoq)的天然反义转录物治疗脂连蛋白(adipoq)相关疾病 |
US8791087B2 (en) | 2009-08-21 | 2014-07-29 | Curna, Inc. | Treatment of ‘C terminus of HSP70-interacting protein’ (CHIP)related diseases by inhibition of natural antisense transcript to CHIP |
CA2771172C (en) | 2009-08-25 | 2021-11-30 | Opko Curna, Llc | Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
JP6175236B2 (ja) | 2009-09-25 | 2017-08-09 | カッパーアールエヌエー,インコーポレイテッド | フィラグリン(flg)の発現および活性の調整によるflg関連疾患の処置 |
KR101823702B1 (ko) | 2009-12-16 | 2018-01-30 | 큐알엔에이, 인크. | 막 결합 전사 인자 펩티다제, 부위 1(mbtps1)에 대한 천연 안티센스 전사체의 억제에 의한 mbtps1 관련 질환의 치료 |
CN102869776B (zh) | 2009-12-23 | 2017-06-23 | 库尔纳公司 | 通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病 |
RU2619185C2 (ru) | 2009-12-23 | 2017-05-12 | Курна, Инк. | Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2 |
WO2011090740A2 (en) | 2009-12-29 | 2011-07-28 | Opko Curna, Llc | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
US8962585B2 (en) | 2009-12-29 | 2015-02-24 | Curna, Inc. | Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63 |
KR101853511B1 (ko) | 2009-12-31 | 2018-06-20 | 큐알엔에이, 인크. | 인슐린 수용체 기질 2 및 전사 인자 e3(tfe3)에 대한 천연 안티센스 전사체의 억제에 의한 irs2 관련된 질환의 치료 |
KR101878501B1 (ko) | 2010-01-04 | 2018-08-07 | 큐알엔에이, 인크. | 인터페론 조절 인자 8 (irf8)에 대한 자연 안티센스 전사체의 저해에 의한 인터페론 조절 인자 8 (irf8) 관련된 질환의 치료 |
KR101853509B1 (ko) | 2010-01-06 | 2018-04-30 | 큐알엔에이, 인크. | 췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료 |
CA2786535C (en) | 2010-01-11 | 2019-03-26 | Curna, Inc. | Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg |
JP5981850B2 (ja) | 2010-01-25 | 2016-08-31 | カッパーアールエヌエー,インコーポレイテッド | RNaseH1に対する天然アンチセンス転写物の阻害によるRNaseH1関連疾患の治療 |
JP5976548B2 (ja) | 2010-02-22 | 2016-08-23 | カッパーアールエヌエー,インコーポレイテッド | Pycr1に対する天然アンチセンス転写物の阻害によるピロリン−5−カルボン酸レダクターゼ1(pycr1)関連疾患の治療 |
AU2011232365A1 (en) | 2010-03-24 | 2012-10-25 | Rxi Pharmaceuticals Corporation | RNA interference in dermal and fibrotic indications |
US8980856B2 (en) | 2010-04-02 | 2015-03-17 | Curna, Inc. | Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3 |
WO2011127337A2 (en) | 2010-04-09 | 2011-10-13 | Opko Curna Llc | Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21 |
CA2798218A1 (en) | 2010-05-03 | 2011-11-10 | Curna, Inc. | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
TWI531370B (zh) | 2010-05-14 | 2016-05-01 | 可娜公司 | 藉由抑制par4天然反股轉錄本治療par4相關疾病 |
JP5917497B2 (ja) | 2010-05-26 | 2016-05-18 | カッパーアールエヌエー,インコーポレイテッド | メチオニンスルホキシドレダクターゼa(msra)に対する天然アンチセンス転写物の阻害によるmsra関連疾患の治療 |
EP2576783B1 (en) | 2010-05-26 | 2017-11-29 | CuRNA, Inc. | Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1 |
CN103025873B (zh) | 2010-06-23 | 2018-05-08 | 库尔纳公司 | 通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病 |
JP5998131B2 (ja) | 2010-07-14 | 2016-09-28 | カッパーアールエヌエー,インコーポレイテッド | Discslargehomolog(dlg)dlg1への天然アンチセンス転写物の阻害によるdlg関連疾患の治療 |
RU2624048C2 (ru) | 2010-10-06 | 2017-06-30 | Курна, Инк. | Лечение заболеваний, связанных с геном сиалидазы 4 (neu4), путем ингибирования природного антисмыслового транскрипта гена neu4 |
WO2012054723A2 (en) | 2010-10-22 | 2012-04-26 | Opko Curna Llc | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
US10000752B2 (en) | 2010-11-18 | 2018-06-19 | Curna, Inc. | Antagonat compositions and methods of use |
KR102010598B1 (ko) | 2010-11-23 | 2019-08-13 | 큐알엔에이, 인크. | Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료 |
RU2620980C2 (ru) | 2011-06-09 | 2017-05-30 | Курна, Инк. | Лечение заболеваний, связанных с фратаксином (fxn), путем ингибирования природного антисмыслового транскрипта fxn |
EA029151B1 (ru) | 2011-09-06 | 2018-02-28 | Курна, Инк. | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АЛЬФА-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ |
US9308163B2 (en) | 2012-02-15 | 2016-04-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of treating and preventing diseases and disorders of the central nervous system |
CN104271142B (zh) | 2012-03-01 | 2017-07-04 | 福斯特斯特林研究公司 | 含有α连接蛋白C‑末端(ACT)肽的局部凝胶 |
WO2013138374A2 (en) | 2012-03-15 | 2013-09-19 | Curna, Inc. | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
US20140274872A1 (en) * | 2013-03-15 | 2014-09-18 | Coda Therapeutics, Inc. | Compositions and treatments based on cadherin modulation |
WO2013148736A1 (en) | 2012-03-27 | 2013-10-03 | Coda Therapeutics, Inc. | Compositions and treatments based on cadherin modulation |
SG11201507211YA (en) * | 2013-03-11 | 2015-10-29 | Univ North Carolina | Compositions and methods for targeting o-linked n-acetylglucosamine transferase and promoting wound healing |
US9156896B2 (en) | 2013-03-15 | 2015-10-13 | Coda Therapeutics, Inc. | Wound healing compositions and treatments |
EP3077050B1 (en) * | 2013-12-04 | 2020-10-21 | Phio Pharmaceuticals Corp. | Methods for treatment of wound healing utilizing chemically modified oligonucleotides |
CA2940648A1 (en) * | 2014-02-25 | 2015-09-03 | Coda Therapeutics, Inc. | Treatment of resistant lesions |
US20170106047A1 (en) * | 2014-06-12 | 2017-04-20 | The Research Foundation For The State University Of New York | Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina |
EA201790434A1 (ru) | 2014-08-22 | 2017-07-31 | Окленд Юнисервисиз Лимитед | Модуляторы каналов |
WO2016037071A2 (en) | 2014-09-05 | 2016-03-10 | Rxi Pharmaceuticals Corporation | Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1 |
CN116672445A (zh) * | 2016-02-26 | 2023-09-01 | 德克萨斯大学体系董事会 | 连接蛋白(Cx)43半通道结合抗体及其用途 |
JP7495230B2 (ja) | 2017-04-28 | 2024-06-04 | オークランド ユニサービシズ リミテッド | 処置方法および新規構築物 |
EP3685824A1 (en) * | 2019-01-25 | 2020-07-29 | Breitenbronn-Consulting GbR | Composition for administering and releasing oligonucleotides |
WO2023219655A1 (en) * | 2022-05-13 | 2023-11-16 | University Of Utah Research Foundation | Gja1-20k to limited cardiac arrhythmias |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9425930D0 (en) | 1994-12-22 | 1995-02-22 | Procter & Gamble | Silicone compositions |
US6149904A (en) * | 1996-01-31 | 2000-11-21 | The Regents Of The University Of California | Method for inhibiting tumor cell growth by administering to tumor cells expressing a nucleic acid encoding a connexin and a pro-drug |
EP1464703A3 (en) * | 1996-03-07 | 2004-10-13 | Eisai Co., Ltd. | Canine adhesion molecule occludin |
WO1998002150A1 (en) * | 1996-07-17 | 1998-01-22 | Medtronic, Inc. | System for genetically treating cardiac conduction disturbances |
CA2273203A1 (en) * | 1996-12-02 | 1998-06-11 | Dyad Pharmaceutical Corporation | Antisense inhibition of human adhesion molecules |
JP4404479B2 (ja) * | 1997-12-09 | 2010-01-27 | チルドレンズ・メディカル・センター・コーポレイション | 血管内皮増殖因子の可溶性インヒビターおよびその使用 |
WO2000044409A1 (en) * | 1999-01-27 | 2000-08-03 | University College London | Formulations comprising antisense nucleotides to connexins |
US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
-
2000
- 2000-01-27 WO PCT/GB2000/000238 patent/WO2000044409A1/en active IP Right Grant
- 2000-01-27 US US09/890,363 patent/US7098190B1/en not_active Expired - Lifetime
- 2000-01-27 PT PT100131804T patent/PT2314321E/pt unknown
- 2000-01-27 AU AU21193/00A patent/AU776512B2/en not_active Ceased
- 2000-01-27 DK DK00901236T patent/DK1146908T3/da active
- 2000-01-27 ES ES05016736T patent/ES2377749T3/es not_active Expired - Lifetime
- 2000-01-27 PT PT05016736T patent/PT1621212E/pt unknown
- 2000-01-27 ES ES00901236T patent/ES2245638T3/es not_active Expired - Lifetime
- 2000-01-27 DK DK10013180.4T patent/DK2314321T3/da active
- 2000-01-27 ES ES10013180.4T patent/ES2498745T3/es not_active Expired - Lifetime
- 2000-01-27 AT AT00901236T patent/ATE300959T1/de active
- 2000-01-27 EP EP10013180.4A patent/EP2314321B1/en not_active Expired - Lifetime
- 2000-01-27 EP EP00901236A patent/EP1146908B1/en not_active Expired - Lifetime
- 2000-01-27 CA CA2361251A patent/CA2361251C/en not_active Expired - Fee Related
- 2000-01-27 EP EP05016736A patent/EP1621212B1/en not_active Expired - Lifetime
- 2000-01-27 NZ NZ513154A patent/NZ513154A/xx not_active IP Right Cessation
- 2000-01-27 CA CA2730386A patent/CA2730386C/en not_active Expired - Fee Related
- 2000-01-27 DK DK05016736.0T patent/DK1621212T3/da active
- 2000-01-27 AT AT05016736T patent/ATE533515T1/de active
- 2000-01-27 DE DE60021700T patent/DE60021700T2/de not_active Expired - Lifetime
- 2000-01-27 JP JP2000595711A patent/JP4994533B2/ja not_active Expired - Lifetime
- 2000-01-27 PT PT00901236T patent/PT1146908E/pt unknown
-
2006
- 2006-06-05 US US11/447,599 patent/US20070037765A1/en not_active Abandoned
- 2006-08-25 US US11/510,498 patent/US7879811B2/en not_active Expired - Fee Related
- 2006-08-25 US US11/510,496 patent/US7919474B2/en not_active Expired - Fee Related
- 2006-08-25 US US11/510,280 patent/US7615540B2/en not_active Expired - Fee Related
- 2006-08-29 US US11/512,730 patent/US20070072819A1/en not_active Abandoned
- 2006-08-29 US US11/512,725 patent/US20080249041A1/en not_active Abandoned
- 2006-08-29 US US11/512,728 patent/US20070066555A1/en not_active Abandoned
- 2006-08-29 US US11/512,735 patent/US7902164B2/en not_active Expired - Fee Related
-
2009
- 2009-11-30 US US12/592,668 patent/US8314074B2/en not_active Expired - Fee Related
-
2011
- 2011-08-19 JP JP2011179832A patent/JP2012041342A/ja active Pending
-
2012
- 2012-02-09 CY CY20121100139T patent/CY1112557T1/el unknown
- 2012-11-19 US US13/681,383 patent/US9193754B2/en not_active Expired - Fee Related
-
2013
- 2013-01-30 JP JP2013015171A patent/JP5705890B2/ja not_active Expired - Lifetime
- 2013-01-30 JP JP2013015172A patent/JP5736397B2/ja not_active Expired - Lifetime
-
2014
- 2014-09-03 CY CY20141100703T patent/CY1115521T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT2314321E (pt) | Elemento de encaminhamento de um fluido de refrigeração de uma ferramenta de corte e processo para este encaminhamento | |
EP1041880A4 (en) | ADMINISTRATION OF ARGININE TO OBTAIN A WELLBEING EFFECT | |
IL187513A0 (en) | Use of (s,s)-reboxetine in the treatment of pain conditions and incontinence | |
MY135988A (en) | Additive for improving the water resistance of cosmetic or dermatological formulations | |
NZ336511A (en) | Treating prostatic diseases using delayed and/or sustained release formulations of activated vitamin D | |
MX9703694A (es) | Tratamiento profilactico y terapeutico de la sensibilizacion e irritacion de la piel. | |
CA2404810A1 (en) | Topical composition having undifferentiated plant seed cells and method for using same | |
EP1563844A3 (en) | Wound healing formulations containing human plasma fibronectin | |
WO2000078341A8 (en) | A method for the prophylaxis and/or treatment of medical disorders | |
WO1997001343A3 (fr) | Utilisation comme substances therapeutiquement actives ou produits cosmetiques des sophorolipides, en particulier pour le traitement de la peau | |
AU2001240940A1 (en) | Cosmetic and dermatological composition for psoriatic skin, scalp treatment and care | |
HK1025504A1 (en) | Use of latency associated peptide for the manufacture of a medicament for increasing wound healing | |
JP2004500353A5 (pt) | ||
EP0471135B1 (en) | Composition for the promotion of hair growth | |
MXPA02012075A (es) | Composicion para mediar el dolor y aparato y metodo para utilizarla. | |
BR0116293A (pt) | Composição tópica, e, método para prevenir, melhorar ou tratar a hiperpigmentação da pele | |
CA2222698A1 (fr) | Utilisation d'antagonistes de la bradykinine pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute | |
IT1258069B (it) | Composizione per uso topico avente attivita' di stimolo per la ricrescita, di rinvigorimento, di prevenzione dell'ingrigimento e di ripigmentazione naturale dei capelli | |
EP1557163A4 (en) | THERAPEUTIC AGENT FOR CONTRACTING MUCOSAL TISSUE, METHOD FOR TREATING DISEASES ASSOCIATED WITH MUCOSAL TISSUES, INJECTOR AND THERAPEUTIC KIT | |
WO1994004184A3 (en) | Method of decreasing cutaneous senescence | |
GB9715085D0 (en) | Gene therapy vehicle | |
IE810489L (en) | Composition for topical application | |
AU6968098A (en) | Topical treatment of skin diseases and eye afflictions | |
AU3952300A (en) | Method to reduce hair loss and stimulate hair regrowth | |
GB2293604B (en) | Dermal fibroblast cells containing muscle-specific DNA and the use of dermal fibroblast cells in the treatment of muscular disorders |